ATE239491T1 - Verbesserte zusammensetzungen und verfahren zur chemodenervation mit neurotoxinen - Google Patents

Verbesserte zusammensetzungen und verfahren zur chemodenervation mit neurotoxinen

Info

Publication number
ATE239491T1
ATE239491T1 AT96917968T AT96917968T ATE239491T1 AT E239491 T1 ATE239491 T1 AT E239491T1 AT 96917968 T AT96917968 T AT 96917968T AT 96917968 T AT96917968 T AT 96917968T AT E239491 T1 ATE239491 T1 AT E239491T1
Authority
AT
Austria
Prior art keywords
neurotoxins
methods
admixtures
neurotoxin
compositions
Prior art date
Application number
AT96917968T
Other languages
English (en)
Inventor
L Bruce Pearce
Eric R First
Original Assignee
L Bruce Pearce
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by L Bruce Pearce filed Critical L Bruce Pearce
Application granted granted Critical
Publication of ATE239491T1 publication Critical patent/ATE239491T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Detergent Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
AT96917968T 1995-06-06 1996-06-04 Verbesserte zusammensetzungen und verfahren zur chemodenervation mit neurotoxinen ATE239491T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46576795A 1995-06-06 1995-06-06
PCT/US1996/008534 WO1996039167A1 (en) 1995-06-06 1996-06-04 Improved compositions and methods for chemodenervation using neurotoxins

Publications (1)

Publication Number Publication Date
ATE239491T1 true ATE239491T1 (de) 2003-05-15

Family

ID=23849078

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96917968T ATE239491T1 (de) 1995-06-06 1996-06-04 Verbesserte zusammensetzungen und verfahren zur chemodenervation mit neurotoxinen

Country Status (8)

Country Link
US (1) US6087327A (de)
EP (1) EP0773788B1 (de)
AT (1) ATE239491T1 (de)
AU (1) AU6034396A (de)
DE (1) DE69627963T2 (de)
DK (1) DK0773788T3 (de)
ES (1) ES2198484T3 (de)
WO (1) WO1996039167A1 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW574036B (en) 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
US6545126B1 (en) * 1999-03-18 2003-04-08 Wisconsin Alumni Research Foundation Chimeric toxins
DE19925739A1 (de) * 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
US6261572B1 (en) 2000-01-11 2001-07-17 Allergan Sales, Inc. Method for treating a pancreatic disorder with a neurotoxin
US6337075B1 (en) 2000-01-11 2002-01-08 Allergan Sales, Inc. Methods for treating diabetes
US6143306A (en) * 2000-01-11 2000-11-07 Allergan Sales, Inc. Methods for treating pancreatic disorders
JP2003522154A (ja) * 2000-02-08 2003-07-22 アラーガン、インコーポレイテッド ボツリヌス毒素医薬組成物
US8632785B2 (en) * 2000-02-08 2014-01-21 Allergan, Inc. Clostridial toxin pharmaceutical composition containing a gelatin fragment
US7780967B2 (en) 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US20060269575A1 (en) * 2000-02-08 2006-11-30 Allergan, Inc. Botulinum toxin pharmaceutical compositions formulated with recombinant albumin
US20030138460A1 (en) * 2000-02-08 2003-07-24 Allergan, Inc Methods of treating animals with botulinum toxin pharmaceutical compositions
JP2004521067A (ja) * 2000-06-28 2004-07-15 サンダース，イラ 動物（哺乳動物）における有用な用途を目的とする破傷風毒素の使用方法
US7273722B2 (en) 2000-11-29 2007-09-25 Allergan, Inc. Neurotoxins with enhanced target specificity
US7115399B2 (en) * 2001-07-31 2006-10-03 Allergan, Inc. Pinna reflex assay
US20030113349A1 (en) * 2001-12-18 2003-06-19 Coleman William P. Topically applied clostridium botulinum toxin compositions and treatment methods
US7022329B2 (en) * 2002-02-25 2006-04-04 Allergan, Inc. Method for treating neurogenic inflammation pain with botulinum toxin and substance P components
US7691394B2 (en) * 2002-05-28 2010-04-06 Botulinum Toxin Research Associates, Inc. High-potency botulinum toxin formulations
US20040009180A1 (en) * 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
ATE426408T1 (de) * 2002-12-20 2009-04-15 Botulinum Toxin Res Ass Inc Pharmazeutische zusammensetzungen enthaltend botulinumtoxin und humanes serum-albumin
US7276244B2 (en) * 2004-02-12 2007-10-02 Philip Radovic Methods of treating abnormalities of the first metatarsophalangeal joint of the foot
US20050220821A1 (en) * 2004-03-31 2005-10-06 Allergan, Inc. Pressure sore treatment
US8323666B2 (en) 2005-08-01 2012-12-04 Allergan, Inc. Botulinum toxin compositions
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
US8137677B2 (en) 2005-10-06 2012-03-20 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions
US20070128226A1 (en) * 2005-12-01 2007-06-07 Philip Radovic Methods of treating pain associated with abnormalities of the first metatarsophalangeal joint of the foot
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
WO2009139739A1 (en) * 2006-02-14 2009-11-19 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions comprising a combination of botulinum toxin a and botulinum toxin b for treating conditions characterized by unwanted or excessive presynaptic neuronal activity or secretion
EP2015773A4 (de) * 2006-04-27 2010-05-05 Anterios Inc Prüfung der effekte topischer verabreichung chemisch denervierender pharmazeutika
US20080113051A1 (en) * 2006-11-13 2008-05-15 Allergan, Inc. Methods for alleviating tattoo pain
WO2008070538A2 (en) 2006-12-01 2008-06-12 Anterios, Inc. Micellar nanoparticles comprising botulinum toxin
US9107815B2 (en) 2008-02-22 2015-08-18 Allergan, Inc. Sustained release poloxamer containing pharmaceutical compositions
KR102080429B1 (ko) * 2008-06-26 2020-02-21 안테리오스, 인코퍼레이티드 경피 운반
EP2364168A1 (de) 2008-12-04 2011-09-14 Botulinum Toxin Research Associates, Inc. Verlängerte botulinustoxin-formulierung zur anwendung bei menschen oder säugetieren
US8129139B2 (en) 2009-07-13 2012-03-06 Allergan, Inc. Process for obtaining botulinum neurotoxin
JP5943258B2 (ja) * 2011-01-24 2016-07-05 アンテリオス， インコーポレイテッド ナノ粒子組成物、その製剤およびその使用
US9393291B2 (en) 2012-04-12 2016-07-19 Botulinum Toxin Research Associates, Inc. Use of botulinum toxin for the treatment of cerebrovascular disease, renovascular and retinovascular circulatory beds
MX370929B (es) 2012-10-28 2020-01-08 Revance Therapeutics Inc Composiciones y usos de las mismas para el tratamiento seguro de la rinitis.
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
US9901627B2 (en) 2014-07-18 2018-02-27 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
IL265109B2 (en) 2016-09-13 2024-05-01 Allergan Inc Stabilized non-protein clostridial toxin compositions
EP3541358A1 (de) 2016-11-21 2019-09-25 Eirion Therapeutics, Inc. Transdermale verabreichung von grossen wirkstoffen

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5183462A (en) * 1990-08-21 1993-02-02 Associated Synapse Biologics Controlled administration of chemodenervating pharmaceuticals
US5401243A (en) * 1990-08-21 1995-03-28 Associated Synapse Biologics Controlled administration of chemodenervating pharmaceuticals
WO1994000481A1 (en) * 1992-06-23 1994-01-06 Associated Synapse Biologics Pharmaceutical composition containing botulinum b complex
US5562907A (en) * 1993-05-14 1996-10-08 Arnon; Stephen S. Method to prevent side-effects and insensitivity to the therapeutic uses of toxins
JP4249802B2 (ja) * 1993-06-10 2009-04-08 アラーガン、インコーポレイテッド 神経筋疾患および症状を処置するためのボツリヌス毒素組み合わせ
AU689115B2 (en) * 1993-06-10 1998-03-26 Allergan, Inc. Treatment of neuromuscular disorders and conditions with different botulinum serotype
US5512547A (en) * 1994-10-13 1996-04-30 Wisconsin Alumni Research Foundation Pharmaceutical composition of botulinum neurotoxin and method of preparation

Also Published As

Publication number Publication date
US6087327A (en) 2000-07-11
DK0773788T3 (da) 2003-09-01
DE69627963D1 (de) 2003-06-12
ES2198484T3 (es) 2004-02-01
WO1996039167A1 (en) 1996-12-12
EP0773788B1 (de) 2003-05-07
EP0773788A1 (de) 1997-05-21
DE69627963T2 (de) 2004-03-04
AU6034396A (en) 1996-12-24

Similar Documents

Publication Publication Date Title
DE69627963D1 (de) Verbesserte zusammensetzungen und verfahren zur chemodenervation mit neurotoxinen
DE69940439D1 (de) Streptococcus pneumoniae proteine und immunogene fragmente für impstoffe
ATE553118T1 (de) Modifiziertes clostridiumtoxin mit geänderter biologischer persistenz
WO2002008268A3 (en) Leucine-based motif and clostridial neurotoxins
DK0544777T3 (da) Enzymatisk detergentsammensætning og fremgangsmåde til enzymstabilisering
ES2182887T3 (es) Activador de especificidad tisular activo en la prostata.
BG103977A (en) Low molecular rotamase enzymic activity inhibitors
DE60142839D1 (de) Botulinum Toxin zur Behandlung von akuten Verletzungen der Skelettmuskeln
BR9909129A (pt) Conjugados de proteases
BR9917152A (pt) Composição para tratamento terapêutico ou profilático de infecção estreptocócica e método e uso respectivos
DE60007001D1 (de) Neurotoxine zur behandlung von pankreatischen krankheiten
KR970064594A (ko) 노화방지용 화장품 조성물
EP1024827A4 (de) Zusammensetzungen und methoden zur systemischen verabreichung von oralen impfstoffen und therapeutischen wirkstoffen
WO2001082961A3 (en) Methods for treating bone tumors
FI925787A0 (fi) Proteolytiska enzymers sackarinderivatinhibitorer
DK0418945T3 (da) Forgreningsenzym og dets anvendelse
Martinez et al. Isolation of a hemorrhagic toxin from Mojave rattlesnake (Crotalus scutulatus scutulatus) venom
ATE384797T1 (de) Streptococcus pyogenes virulenz gene und proteine und ihre verwendungen
AU2888702A (en) Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy
WO2005016232A3 (en) Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
Smyth et al. The potent mitogen Pasteurella multocida toxin is highly resistant to proteolysis but becomes susceptible at lysosomal pH
NO951277L (no) Desulfatohirudin med höy molekylvekt
ATE210460T1 (de) Zusammensetzungen, welche adp-ribosyltransferase- aktivität aufweisen und methoden für ihre herstellung und die verwendung derselben
PE46999A1 (es) Inhibidores de cicloalquilo de la enzima farnesiltransferasa de las proteinas
EA200100701A1 (ru) Белки наружной поверхности, их гены и их применение

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties